Roth Capital specializes in mergers and acquisitions (as well as other things). Who knows what this means?

Barto, BE PATIENT! Just wait another six years......it'll all work out. I have another 1-2 months and may have to bail. I hate that the CEO has no regard for the shareholders. I am in too deep to leave now but may have no choice.

Snug, you make a good point that an objective observer of this company would have sold out long ago. Obviously those of us who have bought into this new mode of cancer therapy are not objective observers.
BUT, what we are doing does not fit the definition of insanity and I get tired of that quote. I admit stupidity but not insanity.
Look it up.??????

C'mon guys, BE PATIENT. It has only been six fu****g years since I bought into this start up??????.

A great day to buy BPTH. My target was close to $1 but paid a little more as every purchase drove the ask price up. Time to rebalance the portfolio so I raised cash by selling the big growth stocks. It may take a week or so for things to settle down and then reinvest the cash.

I am not much of a technical analyst but it looks like $1.10-1.15 could be the bottom although a brief drop to .99 would not surprise me. I think the "shorts" seem to disappear under $1.20.
Is anyone betting on good news release for next week?

I assume the PR firm is developing their program for BioPath. Do you think they are purposely watching the price drop to bring their clients in at a better price. Could they be manipulating the price to produce a cheaper buy in point?
At any rate, the price is lower than I expected and no sign of a turn-around in sight.

Right. Under "full company report", BPTH is listed as a strong buy. But the "Zacks rank" there is no listing. This may mean it is being reevaluated now or they have dropped coverage and have not updated all of the pages?
Since the BioPath web page has dropped the link to Zacks, I suspect it is no longer ranked.

Peter's comments are reassuring and it is good to know that Maxim is sticking with a buy recommendation but I am bothered by Zacks dropping their rating. I am assuming that the three big news releases will concern:
1-results of phase 2 safety study of Grb-2
2-finishing pre clinical work on Grb-2 treating TNBC /IBC
3-applying IND for Bcl-2

I don't understand why it takes six months or longer to dose a total of six patients.......but if the report is positive, we will move on.

An important find, dmoffat. Zack' had given very positive reviews on BPTH and I don't think it was any kind of relationship between the firms. They looked at the potential of liposomal delivery of RNA antisense drugs and thought we had a future. They apparently have dropped the "buy" recommendation and that concerns me. I need some positive news soon or I may start selling

Question: On page 6 of the financial report, paragraph 3 and 4 state that MD Anderson is no longer a 5% stockholder. Did MDA sell a portion of their holdings in the first or second quarter? I see that the U of Texas Health Sciences holds around 3.8 million shares.......is that the "less than 5% "they're talking about?

I think the statement about TNBC and IBC is on page 12 (not page 20) but is clearly stated as it was in the previous quarterly report. I think we are on track for success. Thanks SJ for the careful review of this document, it does help to have a lawyer on our team.

Can anyone explain to me what happened today? This morning the price dropped while someone was buying 95000 shares. The IHUB chart shows buyers outnumbered sellers about 2:1 but the final price was down. Shortanalytics.com shows total buys at about 65,000 shares and shorts at 105,000 shares. Does anyone know what really happened?

Once again, I spoke too soon. Sudden increase in volume driving the price down but the IHUB chart shows most of the action is buying! Looks like major manipulation but can someone explain this to me?

No news today and very little trading in the first hour. I hope Barto is right and we have something positive next week. The wait is painful.

Somebody dumped a lot of shares but it was not new shorting. The short interest today was about 5%, the lowest in a long time. I will be watching closely tomorrow. I admittedly am only prepared for good news.

SJ, let me be clear........... Later! I' m not sure how much later.

SJ, I don't know the answer to your question but it looks like today is not the day. Therefore, it must be later. Any other questions???

Yes, SJ I think they are working with a new IR/PR firm and we will see in the coming weeks if we benefit as we expect. Today may have been the first sign as we had a sudden increase in volume. Are we having fun yet?

Excuse me, I'm trying to pull my foot out of my mouth. It seems that every time I try to say something brilliant and definitive, I am proved wrong. Suddenly we have increased volume and price. But we will see what happens next. Maybe a wave of short sellers?

If we have a PR/IR/marketing program in place, they are not doing anything. Volume remains ridiculously low and falling. This stock is going nowhere without increased volume. If that volume increases next week, I will believe that we have a real IR firm in place. In the meantime, the stock will move 100 shares at a time (and go nowhere).

SJ you made a good move IMO to add to your shares. I think everyone on this board should be thinking BUY, BUY, BUY. The time is right, the price is right and we are closer to the real payoff.

I received a quick albeit brief reply from Peter. He states that the "marketing program" is in place now. We will see the earnings release in the next couple of weeks and he will comment on the PR/IR firm then. He did not comment on specific questions about 1) completion of the safety study, 2) status of preclinical studies of TNBC and IBC, 3) IND for Bcl-2.
We can only hope that we will soon see results of a PR firm doing some good.

Loveu, you are right: the BioPath execs do not care about the short term price but they are looking at the looooong term. I am going to communicate with Peter Nielson (again) today to emphasize my concerns. In the meantime I am a buyer today. I am not in a position to add too many shares as I am over-weighted in BPTH but the chart tells me that this range of $1.18-1.22 looks like the floor. We should take advantage of this slow trading to add shares. I picked up a few thousand shares under $1.22.

I suspect the shorts have left because the price is so low. They had more to gain at $1.50-70 than $1.20. They do not expect the PPS to drop further. I think we have a long way to go up in the next six months. I hope they short it at $1.50 and we destroy them with a short squeeze.

I wonder what her nickname is.
Has anyone heard any news or rumors about progress on an IR firm? I have expected something to happen by months end.

Sarah who?

The shorts on Yahoo finance are silent. The volume of short selling has been very low in the past week. I assume they would like to see a higher selling price but the low volume of buyers has not helped. Again, we need NEWS.

Wow, you are an optimist. Maybe things are quiet because nothing is happening?.......I hope you're right.

I think that the science will determine the eventual destination of BioPath. The failed leadership has slowed us down but the scientists at MD Anderson will produce the only results that matter.

I do not need new info to believe that BPTH will have a successful phase 2 study, but Michael Garrison's purchase of 50000 shares on the open market is BIG. I am not sure he is adding anything as a board member but he knows how to make money!

I assume these are the same investors who met with Peter 2-3 months ago and asked for two seats on the board. I understood that they did not want to remove him as CEO but did want to use their shares to run the company better. I will support them with my shares.

Brett, if your father feels that strongly, does he still own shares in BPTH? Can science win the day even with poor management of the company? How much of a head start does JUNO and ISIS have since starting their first phase 1? And how much cash have those companies bled getting ready for their first FDA approval?
I do not think things are as bleak as suggested in your post but you all know the level of my personal frustration.

Not until 2018?

You are right, they did say they planned to add an investor relations firm as soon as possible. The same letter announced their intention to engage an investment bank to issue at-the-market stock offering. They have delivered on that promise. I assume we will have news about an IR firm eventually.

There were rumors about a new IR firm but I do not recall that the co. said anything about it. Apparently it hasn't happened.

I wondered what that funny taste was.

We have been told that three major goals are expected by end of year: 1. Completion of safety phase of Grb-2 treatment of AML.
2. Completion of preclinical evaluation of Grb-2 treatment of IBC and TNBC
3. IND application for Bcl-2
I hope nobody is holding their breath.

The second half of 2015 has begun. We have been told to expect three major goals

I thought the Russell indices were reset after the close on Friday. Is it your understanding, SJ, that today's selling is still related to Russell reconstitution?